DE2208787C3 - Mittel zur Behandlung von Herpes-Virusinfektionen - Google Patents
Mittel zur Behandlung von Herpes-VirusinfektionenInfo
- Publication number
- DE2208787C3 DE2208787C3 DE2208787A DE2208787A DE2208787C3 DE 2208787 C3 DE2208787 C3 DE 2208787C3 DE 2208787 A DE2208787 A DE 2208787A DE 2208787 A DE2208787 A DE 2208787A DE 2208787 C3 DE2208787 C3 DE 2208787C3
- Authority
- DE
- Germany
- Prior art keywords
- herpes
- mice
- treatment
- phosphonoacetic acid
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000011282 treatment Methods 0.000 title claims description 13
- 206010019972 Herpes viral infections Diseases 0.000 title description 2
- 238000002360 preparation method Methods 0.000 title 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 claims description 47
- 208000015181 infectious disease Diseases 0.000 claims description 14
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 9
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 241000700626 Cowpox virus Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 20
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 206010062639 Herpes dermatitis Diseases 0.000 description 14
- 230000034994 death Effects 0.000 description 10
- 231100000517 death Toxicity 0.000 description 10
- 206010023332 keratitis Diseases 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000028006 Corneal injury Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 2
- 206010019973 Herpes virus infection Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- -1 Phosphonoacetic acid 5-iodo-2'-deoxyuridine Chemical compound 0.000 description 2
- DLGSOJOOYHWROO-WQLSENKSSA-N [(z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960003152 metisazone Drugs 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 231100000456 subacute toxicity Toxicity 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11905671A | 1971-02-25 | 1971-02-25 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2208787A1 DE2208787A1 (de) | 1972-08-31 |
| DE2208787B2 DE2208787B2 (de) | 1979-07-19 |
| DE2208787C3 true DE2208787C3 (de) | 1980-03-27 |
Family
ID=22382341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2208787A Expired DE2208787C3 (de) | 1971-02-25 | 1972-02-24 | Mittel zur Behandlung von Herpes-Virusinfektionen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US3767795A (OSRAM) |
| AU (1) | AU475310B2 (OSRAM) |
| CA (1) | CA1011254A (OSRAM) |
| DE (1) | DE2208787C3 (OSRAM) |
| FR (1) | FR2126442B1 (OSRAM) |
| GB (1) | GB1334327A (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1069526A (en) * | 1976-04-30 | 1980-01-08 | Thomas R. Herrin | Phosphorus esters of phosphonoacetic acid |
| US4052439A (en) * | 1976-04-30 | 1977-10-04 | Abbott Laboratories | Carboxylic esters of phosphonoacetic acid |
| SE7607496L (sv) * | 1976-07-01 | 1978-01-02 | Astra Laekemedel Ab | Sett for bekempning av virusinfektioner |
| US4087522A (en) * | 1976-09-08 | 1978-05-02 | Abbott Laboratories | Amides of phosphonoacetic acid for treating herpes simplex virus type 1 and 2 infections |
| US4150125A (en) * | 1977-09-30 | 1979-04-17 | Abbott Laboratories | Triglyceride ester of phosphonoacetic acid having antiviral activity |
| CA1144937A (en) * | 1977-12-22 | 1983-04-19 | Dke J.E. Helgstrand | Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections |
| DE2941384A1 (de) * | 1979-10-12 | 1981-04-23 | Bayer Ag, 5090 Leverkusen | Phosphono-hydroxy-essigsaeure, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| JPS5711918A (en) * | 1980-06-24 | 1982-01-21 | Tokai Daigaku | Remedy for herpes virus infection in human bodies |
| US4272528A (en) * | 1980-08-14 | 1981-06-09 | Abbott Laboratories | Phosphonoacetyl aminoacids |
| US4902678A (en) * | 1982-02-12 | 1990-02-20 | Syntex (U.S.A.) Inc. | Anti-viral compositions |
| ATE24836T1 (de) * | 1982-02-12 | 1987-01-15 | Ens Bio Logicals Inc | Antivirale zusammensetzungen. |
| IT1150209B (it) * | 1982-03-01 | 1986-12-10 | Ausonia Farma Srl | Composto ad attivita'antivirale, procedimento per la sua preparazione e relative composizioni farmaceutiche |
| US20050171063A1 (en) * | 2003-10-20 | 2005-08-04 | Pawan Malhotra | Use of phosphono derivatives as anti-malarials |
-
1971
- 1971-02-25 US US00119056A patent/US3767795A/en not_active Expired - Lifetime
-
1972
- 1972-02-04 CA CA133,958A patent/CA1011254A/en not_active Expired
- 1972-02-07 GB GB561372A patent/GB1334327A/en not_active Expired
- 1972-02-10 AU AU38885/72A patent/AU475310B2/en not_active Expired
- 1972-02-24 DE DE2208787A patent/DE2208787C3/de not_active Expired
- 1972-02-25 FR FR7206565A patent/FR2126442B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU3888572A (en) | 1973-08-16 |
| FR2126442A1 (OSRAM) | 1972-10-06 |
| FR2126442B1 (OSRAM) | 1975-04-25 |
| DE2208787B2 (de) | 1979-07-19 |
| AU475310B2 (en) | 1976-08-19 |
| GB1334327A (en) | 1973-10-17 |
| US3767795A (en) | 1973-10-23 |
| CA1011254A (en) | 1977-05-31 |
| DE2208787A1 (de) | 1972-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2208787C3 (de) | Mittel zur Behandlung von Herpes-Virusinfektionen | |
| DE2619686C2 (de) | Verwendung eines Lysolecithins zur Tumorbehandlung | |
| DE3734835A1 (de) | Arzneimittel zur ophthalmologischen anwendung | |
| DE69130705T2 (de) | Antivirale zusammensetzungen und verfahren zu ihrer anwendung | |
| DE2610540C2 (de) | Verwendung eines OEP als Wirkstoff enthaltenden injizierbaren Impfstoffes zur Vorbeugung gegen die durch Pseudomonas aeruginosa hervorgerufene Pneumonitis der Nerze | |
| DE2435746C2 (OSRAM) | ||
| DE2823346C2 (de) | Verwendung von Glycinderivaten zur Herstellung von antiviriellen Mitteln | |
| DE69019404T2 (de) | Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen. | |
| DE2655690A1 (de) | Arzneimittelzubereitungen | |
| CH676549A5 (OSRAM) | ||
| DE2753312A1 (de) | Heteropolyanionverbindungen, ihre herstellung und sie enthaltende arzneimittel | |
| DE2818158A1 (de) | 5'-amino-5'-deoxythymidin enthaltendes arzneimittel | |
| DE2929009A1 (de) | Gegen bakterielle erkrankungen wirksame zubereitung | |
| DE3440621A1 (de) | Pharmazeutische zusammensetzung zur bekaempfung von vireninfektionen und deren verwendung | |
| EP0342565B1 (de) | Verwendung des Thiazol-Derivates Tiprotimod zur Herstellung eines Mittels zur Therapie von Virusinfektionen | |
| DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen | |
| DE2610426C2 (de) | Verwendung eines OEP als Wirkstoff enthaltenden Impfstoffes zur Bekämpfung der durch Pseudomonas aeruginosa hervorgerufenen Pneumonitis der Nerze | |
| DE1910716A1 (de) | Antimikrobielles Arzneimittel und dessen Verwendung | |
| DE2036935B2 (de) | Diisonicotinsaeurehydrazid-methansulfonat des d(+)2,2'-(aethylendiimino)-di-l- butanols, verfahren zur herstellung desselben und diese verbindung enthaltende arzneimittel | |
| DD232432A5 (de) | Verfahren zur herstellung des wirkstoffes eines immunomodulator-medikamentes | |
| DE1617659B2 (de) | Interferonbildendes Arzneimittel und dessen Verwendung | |
| DE2835878A1 (de) | Oligosaccharid mit durch glucocorticoide bedingte enzyminduktion verstaerkender wirkung, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel | |
| DE3116232A1 (de) | Nonaprenylamin-derivate und sie enthaltende pharmazeutische mittel | |
| DE2758891A1 (de) | Antivirales mittel und verfahren zu seiner herstellung | |
| DE1816049A1 (de) | Antimalaria-Mittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8339 | Ceased/non-payment of the annual fee |